Pharmacokinetic evaluation of LASSBio-579: An N-phenylpiperazine antipsychotic prototype

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 6, 2008, Pages 699-707

  Conrado, Daniela J ^a   Verli, Hugo ^a   Neves, Gilda ^a   Fraga, Carlos Alberto Manssour ^b   Barreiro, Eliezer J ^b   Rates, Stela Maris Kuze ^a   Dalla Costa, Teresa ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LASSBIO 579; LASSBIO 581; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BRAIN; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PHARMACOKINETICS; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN BINDING; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 43949121414     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.6.0004     Document Type: Article

References (32)

1. Assié, M., Ravailhe, V., Faucillon, V., Newman-Tancredi, A. (2005) Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315: 265-272
2. Blatt, D. H., Leonard, S. W., Traber, M. G. (2001) Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition 17: 799-805
3. Conrado, D. J., Palma, E. C., Fraga, C. A. M., Barreiro, E. J., Rates, M. K., Dalla Costa, T. (2007) Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma. J. Pharm. Biomed. Anal. 43: 677-682
4. Elhwuegi, A. S. (2004) Central monoamines and their role in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28: 435-451
5. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49: 538-544
6. Gaszner, P., Makkos, Z. (2004) Clozapine maintenance therapy in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28: 465-469
7. Hori, R., Okumura, K., Yoshida, H. (1987) Binding of basic drugs to rat lung mitochondria. Pharm. Res. 4: 142-146
8. Ichikawa, J., Meltzer, H. Y. (1998) Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4): S90-S98
9. Kandel, E. R., Schwartz, J. H., Jessel, T. M. (2000) Principles of neural science, 4th edn. McGraw-Hill, New York
10. 2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27: 1081-1090
11. Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157: 514-520
12. Meltzer, H. Y., Li, Z., Kaneda, Y., Ichikawa, J. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27: 1159-1172
13. Menegatti, R. (2001) Planejamento, síntese e avaliação farmacológica de novos candidatos a protótipos de agentes antipsicóticos. Master's Dissertation. Rio de Janeiro, UFRJ
14. 2 receptor ligands. Bioorg. Med. Chem. 11: 4807-4813
15. Millan, M. J. (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J. Pharmacol. Exp. Ther. 295: 853-861
16. Neves, G., Fenner, R., Heckler, A. P., Viana, A. F., Tasso, L., Menegatti, R., Fraga, C. A. M., Barreiro, E. J., Dalla Costa, T., Rates, S. M. K. (2003) Dopaminergic profile of new heterocyclic n-phenylpiperazine derivatives. Braz. J. Med Biol. Res. 36: 625-629
17. Neves, G., Kliemann, M., Betti, A. H., Conrado, D. J., Tasso, L., Fraga, C. A. M., Barreiro, E. J., Dalla Costa, T., Rates, S. M. K. (2007) Hypothermia induced by N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581 is mediated by serotonergic neurotransmission. Pharmacol. Biochem. Behav. 89: 23-30
18. Ninan, I., Kulkarni, S. K., (1999). Antagonism by pimozide of olanzapine-induced hypothermia. Fundam. Clin. Pharmacol. 13: 541-546
19. Nix, D. E., Goodwin, S. D., Peloquin, C. A., Rotella, D. L., Schentag, J. J. (1991) Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents Chemother. 35: 1947-1952
20. Oerther, S., Ahlenius, S. (2000) Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurement in the rat. J. Pharmacol. Exp. Ther. 292: 731-736
21. Owens, D. G. C. (1996) Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs 51: 895-930
22. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl.) 144: 20-29
23. Schwartz, P. J., Wehr, T. A., Rosenthal, N. E., Bartko, J. J., Oren, D. A., Leutke, C., Murphy, D. L. (1995) Serotonin and thermoregulation. Physiologic and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects. Neuropsychopharmacology 13: 105-115
24. Stahl, S. M. (2000) Essential psychofarmacology - neuroscientific basis and practical applications, 2nd edn., Cambridge University Press, New York
25. Svensson, T. H. (2003) Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clin. Neurosci. Res. 3: 34-4-6
26. Tasso, L., Neves, G., Menegatti, R., Fraga, C. A. M., Barreiro, E. J., Eifler-Lima, V. L., Rates, S. M. K., Dalla Costa, T. (2005) Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. Eur. J. Pharm. Biopharm. 26: 194-202
27. Toon, S., Rowland, M. (1983) Structure-pharmacokinetic relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225: 752-763
28. Triplett, J. W., Hayden, T. L., Mcwhorter, L. K., Gautam, S. R., Kim, E. E., Bourne, D. W. A. (1985) Determination of gallium concentration in "blood-free" tissues using a radiolabeled blood marker. J. Pharm. Sci. 74: 1007-1009
29. Vallone, D., Picetti, R., Borrelli, E. (2000) Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 24: 125-132
30. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614
31. Weinshenker, D., Szot, P. (2002) The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol. Ther. 94: 213-233
32. Westerink, B. H. C. (2002) Can antipsychotic drugs be classified by their effects on a particular group of neurons in the brain? Eur. J. Pharmacol. 455: 1-18